A1ALM

N-{(2R)-1-imino-3-[(3R)-2-oxopyrrolidin-3-yl]propan-2-yl}-N~2~-[4-(6-methoxypyridin-3-yl)benzoyl]-L-leucinamide

Created:	2024-04-09
Last modified:	2025-04-16

Find Related PDB Entry
1 entries where A1ALM is covalently linked to polymer or other heterogen groups

Find related ligands:

Similar Ligands (Stereospecific) Similar Ligands (including Stereoisomers) Similar Ligands (Quick Screen) Similar Ligands (Substructure Stereospecific) Similar Ligands (Substructure including Stereoisomers)

Chemical Details
Formal Charge	0
Atom Count	68
Chiral Atom Count	3
Bond Count	70
Aromatic Bond Count	12

2D diagram of A1ALM

Toggle Hydrogen Toggle Labels

Chemical Component Summary
Name	N-{(2R)-1-imino-3-[(3R)-2-oxopyrrolidin-3-yl]propan-2-yl}-N~2~-[4-(6-methoxypyridin-3-yl)benzoyl]-L-leucinamide
Systematic Name (OpenEye OEToolkits)	~{N}-[(2~{S})-1-[[(2~{S})-1-azanylidene-3-[(3~{S})-2-oxidanylidenepyrrolidin-3-yl]propan-2-yl]amino]-4-methyl-1-oxidanylidene-pentan-2-yl]-4-(6-methoxypyridin-3-yl)benzamide
Formula	C₂₆ H₃₃ N₅ O₄
Molecular Weight	479.571
Type	NON-POLYMER

Chemical Descriptors
Type	Program	Version	Descriptor
SMILES	ACDLabs	12.01	COc1ccc(cn1)c1ccc(cc1)C(=O)NC(CC(C)C)C(=O)NC(CC1CCNC1=O)C=N
SMILES	CACTVS	3.385	COc1ccc(cn1)c2ccc(cc2)C(=O)N[CH](CC(C)C)C(=O)N[CH](C[CH]3CCNC3=O)C=N
SMILES	OpenEye OEToolkits	2.0.7	CC(C)CC(C(=O)NC(CC1CCNC1=O)C=N)NC(=O)c2ccc(cc2)c3ccc(nc3)OC
Canonical SMILES	CACTVS	3.385	COc1ccc(cn1)c2ccc(cc2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C[C@@H]3CCNC3=O)C=N
Canonical SMILES	OpenEye OEToolkits	2.0.7	CC(C)C[C@@H](C(=O)N[C@@H](C[C@@H]1CCNC1=O)C=N)NC(=O)c2ccc(cc2)c3ccc(nc3)OC
InChI	InChI	1.06	InChI=1S/C26H33N5O4/c1-16(2)12-22(26(34)30-21(14-27)13-19-10-11-28-24(19)32)31-25(33)18-6-4-17(5-7-18)20-8-9-23(35-3)29-15-20/h4-9,14-16,19,21-22,27H,10-13H2,1-3H3,(H,28,32)(H,30,34)(H,31,33)/b27-14+/t19-,21-,22-/m0/s1
InChIKey	InChI	1.06	NQIDETVWOWSWJR-ZFEVDKSVSA-N

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.